Kirkstal22 Feb 2026 15:44
QV1200 system is it commercially viable considering its been around for nearly 10 years
Yes, the QV1200 system remains commercially viable because it has transitioned from an early-stage academic tool into a specialized, industry-focused platform. Despite being on the market for nearly a decade, its manufacturer, Kirkstall, has recently updated the system and sharpened its commercial strategy to target high-growth sectors.
Its continued viability is driven by several key factors:
1. Modern Technical Updates
The system has not remained static. The Quasi Vivo® Advance (QV1200) update introduced:
* Optical Windows: Equipped with top and bottom optical windows for real-time, high-resolution imaging.
* Material Improvements: It now uses inert, biocompatible resin instead of PDMS(Polydimethylsiloxane), which eliminates the issue of non-specific drug binding—a critical requirement for accurate pharmacokinetic studies.
* Interconnectivity: Supports up to 12 interconnected chambers for complex, multi-organoid modelling.
*
2. Strategic Market Positioning
The system is currently used in over 100 labs worldwide, including top-tier medical research universities.
* Industry Adoption: Kirkstall recently hired specialized leadership to focus on pharmaceutical companies and Contract Research Organisations (CROs) with high-throughput testing needs.
* New Contracts: It was recently adopted by a leading developer of novel RNA therapeutics and companies involved in food additive safety.
* Cost-Effectiveness: It is marketed as an affordable alternative to more complex Organ-on-a-Chip systems, making it accessible for labs that need to scale up their testing without massive capital expenditure.
3. Application Longevity
The QV1200 remains relevant because it addresses permanent challenges in drug development, such as:
* Blood-Brain Barrier (BBB) Research:Precise evaluation of drug permeability.
* Chronic Toxicity: Capability for long-term culture and repeat dosage studies.
* Human Relevance: Mimicking dynamic fluid flow (apical and basolateral) which traditional static 2D cultures cannot achieve.
*
* It asked if I wanted to compare against competitors so i said yes
*
* Key Strategic Differences
* Physiological Fidelity vs. Volume: While microfluidic systems like Emulate excel at mimicking precise laminar shear stress, the Kirkstall QV1200 is better suited for experiments requiring larger tissue volumes (e.g., patient biopsies or thick 3D scaffolds) that cannot fit into narrow microchannels.
* Pharmacokinetics (PK) Accuracy: The QV1200’s shift away from PDMS to inert resin is a major commercial advantage over older microfluidic chips, as it prevents the "sponge effect" where hydrophobic drugs are absorbed into the material, skewing results.
* Integration: The QV1200 is designed for researchers who want to upgrade standard static 2D/3D cultures into dynamic flow systems without abandoning their existing protocols or purchasin
Sign In
Follow the stocks
